dm+d

Unassigned

New Medicines

Newly diagnosed isocitrate dehydrogenase isozyme 1 (IDH1) wild-type glioma - in combination with temozolamide and radiotherapy

Information

New molecular entity
Laminar Pharmaceuticals
Laminar Pharmaceuticals

Development and Regulatory status

Phase III Clinical Trials
Phase III Clinical Trials
None
Yes

Category

An activator of sphingomyelin synthase 1 (SMS1), a key enzyme that regulates phospholipid concentrations in the plasma membrane of cancer cells. Taken daily for 4 weeks, then daily for the first 3 weeks of 4 cycles, continued until progression.
Gliomas with mutated IDH1 and IDH2 have improved prognosis compared to gliomas with wild-type IDH. IDH1 mutation is present in ~80% of grade II-III gliomas and secondary GBM. Gliomas that are wild-type for IDH appear to rapidly acquire multiple complex genetic alterations, including amplification or mutation of EGFR, and loss of the PTEN gene, and become glioblastomas very early in their development [1].
Newly diagnosed isocitrate dehydrogenase isozyme 1 (IDH1) wild-type glioma - in combination with temozolamide and radiotherapy
Oral

Evidence based evaluations